While stimulating HIF signaling, such as through inhibiting PHD activity, may be advisable for certain diseases including myocardial infarction [160] or ischemia-induced tissue necrosis [161], the inhibition of HIFs and 2-OG-dependent enzymes is a primary objective in cancer treatment. Here, PDC is linked to cancer.